Stockscreener 앱 받기
94.83
3.87%
3.53
시장 영업 전:
94.83
전일 마감가:
$91.30
열려 있는:
$91.94
하루 거래량:
782.72K
Relative Volume:
0.99
시가총액:
$6.05B
수익:
$46.02M
순이익/손실:
$-130.15M
주가수익비율:
-46.42
EPS:
-2.0427
순현금흐름:
$56.08M
1주 성능:
+8.87%
1개월 성능:
+13.84%
6개월 성능:
+59.11%
1년 성능:
+145.29%
1일 변동 폭
$91.03
$95.43
1주일 범위
$85.60
$95.43
52주 변동 폭
$37.66
$96.54
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
명칭
Protagonist Therapeutics Inc
전화
(510) 474-0170
주소
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Compare PTGX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
94.83 | 5.83B | 46.02M | -130.15M | 56.08M | -2.0427 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-17 | 개시 | Barclays | Overweight |
| 2025-09-12 | 개시 | Leerink Partners | Outperform |
| 2025-06-17 | 개시 | Citigroup | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Outperform |
| 2024-12-06 | 개시 | Goldman | Neutral |
| 2024-11-05 | 개시 | Wedbush | Outperform |
| 2024-09-24 | 개시 | TD Cowen | Buy |
| 2024-09-09 | 개시 | Truist | Buy |
| 2023-10-30 | 개시 | CapitalOne | Overweight |
| 2023-05-25 | 재개 | Jefferies | Buy |
| 2022-08-25 | 개시 | JMP Securities | Mkt Outperform |
| 2022-02-11 | 개시 | BTIG Research | Buy |
| 2021-10-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-10-11 | 업그레이드 | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-05-24 | 개시 | JMP Securities | Mkt Outperform |
| 2021-05-24 | 개시 | Northland Capital | Outperform |
| 2021-01-06 | 개시 | JP Morgan | Overweight |
| 2020-12-16 | 개시 | Piper Sandler | Overweight |
| 2020-09-18 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-15 | 개시 | Jefferies | Buy |
| 2020-05-18 | 재확인 | H.C. Wainwright | Buy |
| 2019-07-08 | 개시 | H.C. Wainwright | Buy |
| 2019-05-09 | 업그레이드 | Stifel | Hold → Buy |
| 2018-12-06 | 개시 | Nomura | Buy |
| 2018-01-29 | 개시 | Stifel | Buy |
| 2017-07-21 | 개시 | BTIG Research | Buy |
모두보기
Protagonist Therapeutics Inc 주식(PTGX)의 최신 뉴스
Johnson & Johnson in talks to acquire Protagonist Therapeutics, source says - AOL.com
Is Protagonist Therapeutics (PTGX) Still Attractive After A 136% One Year Share Price Surge - simplywall.st
JPMorgan Chase & Co. Lowers Stake in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics (PTGX) Target Price Raised by Goldman S - GuruFocus
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $95.00 - MarketBeat
Protagonist Therapeutics, Inc. (PTGX) Stock Analysis: Strong Buy Ratings and a Promising 14.42% Upside Potential - DirectorsTalk Interviews
TD Asset Management Inc Acquires 34,096 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Wedbush Raises Price Target on Protagonist Therapeutics to $100 From $86, Keeps Outperform Rating - marketscreener.com
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera - lelezard.com
Takeda Pharmaceutical and Protagonist Therapeutics Inc (NASDAQ: PTGX) jointly announced that the U.S. Food and Drug Administration (FDA) has officially accepted the New Drug Application (NDA) for their co-developed drug Rusfertide and granted it prior - Bitget
HC Wainwright Has Optimistic Outlook of PTGX Q1 Earnings - MarketBeat
Protagonist Therapeutics, Inc. $PTGX Shares Sold by Vanguard Group Inc. - MarketBeat
Citigroup Inc. Has $10.14 Million Stake in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Why Protagonist Therapeutics (PTGX) Is Up 11.3% After Rusfertide NDA And Collaboration Shift - Yahoo Finance
Protagonist Therapeutics (PTGX) Quarterly Loss Deepens To US$44.4m And Tests Bullish Profitability Narrative - Sahm
PTGX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
A Glimpse Into The Expert Outlook On Protagonist Therapeutics Through 8 Analysts - Sahm
Regulatory Turbulence: FDA Disruptions and U.S. Government Shutdown Threaten Protagonist Therapeutics’ Development Timelines - TipRanks
Understanding the Setup: (PTGX) and Scalable Risk - Stock Traders Daily
Protagonist Therapeutics (PTGX) Gets Price Target Lift from TD C - GuruFocus
TD Cowen Boosts Protagonist Therapeutics (NASDAQ:PTGX) Price Target to $100.00 - MarketBeat
PTGX: Today's Analyst Ratings and Price Target Updates | PTGX St - GuruFocus
Protagonist Therapeutics (PTGX) Sees Analyst Rating Update from Barclays | PTGX Stock News - GuruFocus
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $113.00 at Barclays - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $112.00 - MarketBeat
Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit - AOL.com
Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - The Desert Sun
Citizens raises Protagonist Therapeutics stock price target on drug approvals - Investing.com UK
Decoding Protagonist Therapeutics Inc (PTGX): A Strategic SWOT I - GuruFocus
CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - The Register-Guard
Protagonist Therapeutics (NASDAQ:PTGX) Posts Earnings Results, Misses Expectations By $0.16 EPS - MarketBeat
Protagonist Therapeutics: Fourth Quarter Earnings Overview - Bitget
Protagonist Therapeutics: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - FinanzNachrichten.de
Protagonist Therapeutics Q4 Earnings Summary & Key Takeaways - Benzinga
Protagonist Therapeutics Q4 revenue drops on lower milestone payments - TradingView
Earnings Flash (PTGX) Protagonist Therapeutics, Inc. Reports Q4 Revenue $7.4M - marketscreener.com
[8-K] Protagonist Therapeutics, Inc Reports Material Event | PTGX SEC FilingForm 8-K - Stock Titan
Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit - The Motley Fool
Protagonist Therapeutics Director Sells 20,000 Shares Amid Strong Stock Performance - AOL.com
Protagonist Therapeutics, Inc. (PTGX) Stock Analysis: A Promising Biotech with 17.7% Upside Potential - DirectorsTalk Interviews
Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in March 2026 - ACCESS Newswire
HC Wainwright raises Protagonist Therapeutics, Inc. (PTGX) target to $117, reiterates buy - MSN
RTW INVESTMENTS, LP Reduces Stake in Protagonist Therapeutics Inc - GuruFocus
Can Protagonist Therapeutics Inc. sustain its profitabilityWeekly Trade Summary & AI Driven Stock Movement Reports - mfd.ru
Protagonist Therapeutics showcases pioneering peptide technology - Traders Union
Lewis Williams Sells 18,000 Shares of Protagonist Therapeutics (NASDAQ:PTGX) Stock - Defense World
Polycythemia Vera Market: Growth Momentum Across 7MM to 2034 – DelveInsight | Novartis, Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharma, Perseus Proteomics - Barchart.com
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Protagonist Therapeutics Inc (PTGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Protagonist Therapeutics Inc 주식 (PTGX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Williams Lewis T | Director |
Feb 17 '26 |
Sale |
82.42 |
18,000 |
1,483,560 |
7,825 |
0.11%
6.00%
자본화:
|
볼륨(24시간):